These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7238762)

  • 21. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP; Simpkins J; Meites J; Moore KE
    Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged decrease of serum prolactin in rat by an ester prodrug of apomorphine.
    Baldessarini RJ; Boyd AE; Kula NS; Borgman RJ
    Psychoneuroendocrinology; 1979; 4(2):173-5. PubMed ID: 523586
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of lithium on hypothalamic-pituitary dopaminergic function.
    Lal S; Nair NP; Guyda H
    Acta Psychiatr Scand; 1978 Jan; 57(1):91-6. PubMed ID: 636903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine studies with dopamine agonists in schizophrenia.
    Rotrosen J; Angrist B; Paquin J
    Psychopharmacol Bull; 1978 Jan; 14(1):14-7. PubMed ID: 625529
    [No Abstract]   [Full Text] [Related]  

  • 25. Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease.
    Durso R; Tamminga CA; Denaro A; Ruggeri S; Chase TN
    Neurology; 1983 Sep; 33(9):1229-32. PubMed ID: 6225034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormones, dopamine receptors and schizophrenia.
    Meltzer HY; Busch D; Fang VS
    Psychoneuroendocrinology; 1981; 6(1):17-36. PubMed ID: 7244055
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of carbamazepine on dopamine- and serotonin-mediated neuroendocrine responses.
    Elphick M; Yang JD; Cowen PJ
    Arch Gen Psychiatry; 1990 Feb; 47(2):135-40. PubMed ID: 2105705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitization and tolerance to apomorphine in men: yawning, growth hormone, nausea, and hyperthermia.
    Szechtman H; Cleghorn JM; Brown GM; Kaplan RD; Franco S; Rosenthal K
    Psychiatry Res; 1988 Mar; 23(3):245-55. PubMed ID: 3387500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects.
    Delva NJ; Brooks DL; Franklin M; al-Said K; Hawken ER; Merali Z; Lawson JS; Ravindran AV
    J Psychiatry Neurosci; 2002 Nov; 27(6):429-37. PubMed ID: 12491576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of dieting and weight loss on neuroendocrine responses to tryptophan, clonidine, and apomorphine in volunteers. Important implications for neuroendocrine investigations in depression.
    Goodwin GM; Fairburn CG; Cowen PJ
    Arch Gen Psychiatry; 1987 Nov; 44(11):952-7. PubMed ID: 3675135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of opiate agonists on growth hormone and prolactin release in rats.
    Shaar CJ; Clemens JA
    Fed Proc; 1980 Jun; 39(8):2539-43. PubMed ID: 6247214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CCK-8 antagonizes apomorphine-induced growth hormone secretion in normal subjects.
    Nair NP; Lal S; Eugenio H; Lizondo E; Thavundayil JX; Wood PL; Etienne P; Guyda H
    Horm Metab Res; 1986 Jan; 18(1):53-5. PubMed ID: 3949282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dopamine and neuroleptics on plasma growth hormone and prolactin in normal men.
    Langer G; Sachar EJ; Halpern FS
    Psychoneuroendocrinology; 1978 Apr; 3(2):165-9. PubMed ID: 704750
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men.
    Lal S; Guyda H; Bikadoroff S
    J Clin Endocrinol Metab; 1977 Apr; 44(4):766-70. PubMed ID: 849986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Hietala J; Koulu M; Scheinin M; Syvälahti E
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CNV and dopamine receptor reactivity: correlations with the apomorphine test.
    Timsit-Berthier M; Mantanus H; Marissiaux P; Ansseau M; Doumont A; Geenen V; Legros JJ
    Electroencephalogr Clin Neurophysiol Suppl; 1986; 38():403-5. PubMed ID: 3466779
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of choline on central dopaminergic function in normal subjects.
    Lal S; Etienne P; Thavundayil J; Nair NP; Collier B; Rastogi R; Guyda H; Schwartz G
    J Neural Transm; 1981; 50(1):29-37. PubMed ID: 7205247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine effects of domperidone: a peripheral dopamine blocking agent.
    Brown GM; Verhaegan H; Van Wimersma Greidanus TB; Brugmans J
    Clin Endocrinol (Oxf); 1981 Sep; 15(3):275-82. PubMed ID: 7307290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of dopaminergic receptors in the regulation of growth hormone secretion.
    Müller EE; Liuzzi A; Cocchi D; Panerai AE; Oppizzi G; Lacatelli V; Mantegazza P; Silvestrini F; Chiodini PG
    Adv Biochem Psychopharmacol; 1977; 16():127-38. PubMed ID: 142419
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacology and neurochemistry of apomorphine.
    Di Chiara G; Gessa GL
    Adv Pharmacol Chemother; 1978; 15():87-160. PubMed ID: 358806
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.